ES2494442T3 - Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico - Google Patents

Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Download PDF

Info

Publication number
ES2494442T3
ES2494442T3 ES10721036.1T ES10721036T ES2494442T3 ES 2494442 T3 ES2494442 T3 ES 2494442T3 ES 10721036 T ES10721036 T ES 10721036T ES 2494442 T3 ES2494442 T3 ES 2494442T3
Authority
ES
Spain
Prior art keywords
isotonicity agent
adjuvant compositions
ionic
ionic isotonicity
adjuvant composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10721036.1T
Other languages
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2494442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2494442T3 publication Critical patent/ES2494442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición adyuvante acuosa que comprende: (a) un agonista de TLR-4 y una saponina, en una formulación liposomal; y (b) un agente de isotonicidad no iónico, en la que la concentración de cloruro de sodio o el potencial iónico en la composición adyuvante es menor de 100 mM.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES10721036.1T 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico Active ES2494442T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
GB0910046 2009-06-10
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (1)

Publication Number Publication Date
ES2494442T3 true ES2494442T3 (es) 2014-09-15

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10721036.1T Active ES2494442T3 (es) 2009-06-10 2010-06-08 Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico

Country Status (31)

Country Link
US (2) US20120087976A1 (es)
EP (1) EP2440242B1 (es)
JP (3) JP5647677B2 (es)
KR (1) KR101473686B1 (es)
CN (2) CN104367997B (es)
AU (1) AU2010257538B2 (es)
BR (1) BRPI1012890B1 (es)
CA (1) CA2764421C (es)
CL (1) CL2011003113A1 (es)
CO (1) CO6440528A2 (es)
CY (1) CY1115522T1 (es)
DK (1) DK2440242T3 (es)
DO (1) DOP2011000346A (es)
EA (1) EA024074B1 (es)
ES (1) ES2494442T3 (es)
GB (1) GB0910046D0 (es)
HR (1) HRP20140792T1 (es)
IL (1) IL216231A0 (es)
MA (1) MA33412B1 (es)
MX (1) MX2011013162A (es)
MY (1) MY159819A (es)
NZ (1) NZ596503A (es)
PE (1) PE20120319A1 (es)
PL (1) PL2440242T3 (es)
PT (1) PT2440242E (es)
RS (1) RS53550B1 (es)
SG (1) SG176638A1 (es)
SI (1) SI2440242T1 (es)
SM (1) SMT201400134B (es)
UA (1) UA104888C2 (es)
WO (1) WO2010142685A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575084T3 (es) 2009-06-10 2016-06-24 Chugai Seiyaku Kabushiki Kaisha Compuesto tetracíclico
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
AU2015236106A1 (en) * 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (MPLA)-containing liposome composition and a saponin
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
KR102584344B1 (ko) 2015-01-16 2023-09-27 추가이 세이야쿠 가부시키가이샤 병용 의약
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
US10695424B2 (en) * 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
CA3061205A1 (en) 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
SG11202001826YA (en) * 2017-10-16 2020-03-30 Adjuvance Technologies Inc Triterpene saponin analogues
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2019106191A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin extraction
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
PL3848361T3 (pl) 2018-09-04 2025-07-07 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania związku tetracyklicznego
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2020245207A1 (en) * 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
BR112021026775A2 (pt) * 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composição que compreende um polipeptídeo de proteína d
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
CN121013730A (zh) * 2023-03-15 2025-11-25 联合免疫股份有限公司 脂质颗粒
TW202600165A (zh) * 2024-02-29 2026-01-01 優億股份有限公司 佐劑組合物、包含該佐劑組合物的藥物組合物以及預防或治療病毒感染、細菌感染、原蟲感染或癌症引起的疾病的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
NZ508013A (en) * 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
WO2006056142A1 (en) * 2004-11-29 2006-06-01 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT2114993E (pt) 2007-01-15 2012-11-28 Glaxosmithkline Biolog Sa Vacina
ES2398492T3 (es) 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
JP5331105B2 (ja) * 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
RS53550B1 (sr) 2015-02-27
CA2764421A1 (en) 2010-12-16
PE20120319A1 (es) 2012-04-16
SMT201400134B (it) 2014-11-10
US20180021417A1 (en) 2018-01-25
EP2440242A1 (en) 2012-04-18
BRPI1012890A2 (en) 2018-02-27
CA2764421C (en) 2016-12-06
AU2010257538B2 (en) 2016-10-20
WO2010142685A1 (en) 2010-12-16
NZ596503A (en) 2013-08-30
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
DOP2011000346A (es) 2012-01-15
PT2440242E (pt) 2014-08-29
CL2011003113A1 (es) 2012-08-31
IL216231A0 (en) 2012-01-31
JP5647677B2 (ja) 2015-01-07
JP5977789B2 (ja) 2016-08-24
AU2010257538A1 (en) 2011-12-08
PL2440242T3 (pl) 2014-11-28
CN104367997B (zh) 2019-01-22
MX2011013162A (es) 2012-01-30
JP2016193912A (ja) 2016-11-17
JP2015042646A (ja) 2015-03-05
US20120087976A1 (en) 2012-04-12
MY159819A (en) 2017-02-15
HRP20140792T1 (hr) 2014-10-10
CY1115522T1 (el) 2017-01-04
JP2012529464A (ja) 2012-11-22
DK2440242T3 (da) 2014-09-01
JP6261647B2 (ja) 2018-01-17
EA024074B1 (ru) 2016-08-31
EA201190286A1 (ru) 2012-06-29
CN102458457A (zh) 2012-05-16
GB0910046D0 (en) 2009-07-22
CN102458457B (zh) 2015-05-20
KR101473686B1 (ko) 2014-12-18
EP2440242B1 (en) 2014-06-25
CO6440528A2 (es) 2012-05-15
CN104367997A (zh) 2015-02-25
BRPI1012890B1 (pt) 2022-03-22
SG176638A1 (en) 2012-01-30
SI2440242T1 (sl) 2014-09-30
KR20120031497A (ko) 2012-04-03

Similar Documents

Publication Publication Date Title
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
AR134413A2 (es) Composiciones de insulina de rápida acción
AR084285A1 (es) Composiciones inmunogenicas
BR112022019073A2 (pt) Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
MX2019003611A (es) Formulaciones novedosas.
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
CR10101A (es) Nueva composición
PE20120326A1 (es) Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
CO6290622A2 (es) Composiciones de activo antitranspirante con un cromatograma sec que presenta una elevada intensidad de pico 4 sec para reducir la transpiración
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
BR112017012978A2 (pt) composições adjuvantes aquosas contendo eletrólitos, composições contendo substância ativa e o uso das mesmas
AR108718A2 (es) Composición
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
ES2486844T3 (es) Sustancia que presenta propiedad antidepresiva